Renovaro/$RENB
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Renovaro
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Ticker
$RENB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
25
ISIN
US29350E1047
Website
Renovaro Metrics
BasicAdvanced
$50M
-
-$0.38
0.61
-
Price and volume
Market cap
$50M
Beta
0.61
52-week high
$2.04
52-week low
$0.27
Average daily volume
6.2M
Financial strength
Current ratio
0.127
Quick ratio
0.094
Long term debt to equity
0.563
Total debt to equity
8.573
Interest coverage (TTM)
-25.16%
Profitability
EBITDA (TTM)
-19.769
Management effectiveness
Return on assets (TTM)
-8.41%
Return on equity (TTM)
-53.17%
Valuation
Price to book
0.54
Price to tangible book (TTM)
-1.96
Price to free cash flow (TTM)
-5.422
Free cash flow yield (TTM)
-18.44%
Free cash flow per share (TTM)
-5.40%
Growth
Earnings per share change (TTM)
-70.56%
3-year earnings per share growth (CAGR)
-21.66%
Renovaro Financial Performance
Revenues and expenses
Renovaro News
AllArticlesVideos
Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs
Accesswire·19 minutes ago
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
GlobeNewsWire·4 weeks ago
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Renovaro stock?
Renovaro (RENB) has a market cap of $50M as of June 30, 2025.
What is the P/E ratio for Renovaro stock?
The price to earnings (P/E) ratio for Renovaro (RENB) stock is 0 as of June 30, 2025.
Does Renovaro stock pay dividends?
No, Renovaro (RENB) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Renovaro dividend payment date?
Renovaro (RENB) stock does not pay dividends to its shareholders.
What is the beta indicator for Renovaro?
Renovaro (RENB) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.